QurAlis is a biotech company focused on developing precision therapeutics for amyotrophic lateral sclerosis (ALS), a terminal disease that causes muscle paralysis through degeneration of the motor system and other neurologic diseases.
QurAlis is developing precision medications to effectively treat ALS and frontotemporal dementia.
QurAlis was founded in 2016 by Dr. Kasper Roet, Dr. Kevin Eggan and Dr. Clifford Woolf. The company is headquartered in Cambridge, Massachusetts.
QurAlis’ strategy is to systematically investigate treatments targeting specific disease-causing mechanisms in patient sub-populations. The company evaluates a wide range of potential treatments through the company’s transformative system that utilizes lab-grown neuronal networks derived from cells of ALS patients.
QurAlis is backed by LS Polaris Innovation Fund, INKEF Capital, Mission BioCapital, Dementia Discovery Fund, Droia Ventures and others. The company raised $42M in a Series A round on May 12, 2020. This brings QurAlis' total funding to $50.5M to date.